THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Adam Schwartz, PresidentSSI Strategy (SSI) is a global boutique Life Sciences consulting firm that is focused on the needs of the medical office including Initial caps. Safety, Medical Affairs, and Clinical Development. SSI views the safety function within Life Science organizations, including clinical safety, PV, and device vigilance as strategic business drivers and an advantage for companies that treat it as such. SSI’s President, Adam Schwartz says, “Our view of the safety function is that it can add significant value to the business by generating scientific insights, driving innovation in scientific analysis, and building trusted relationships with health authorities.” Moving forward, SSI sees the future of the PV function further integrating with other business functions and becoming a strategic advantage for companies as data becomes more readily available through integrated digital health technologies.
For PV leaders to provide maximum value to their businesses they need to continually invest in improving the PV System. SSI believes that leaders need to continually balance between investing in developing innovations to increase insights, improving efficiency to manage costs, and reducing risk by verifying consistent compliance. “We find that helping leaders assess their safety systems to identify the current state and prioritize their needs across the resource constraints of innovation, efficiency, and risk reduction can assist PV teams in proactively maximizing the value they can provide to the business. In addition, this helps ensure that leaders have a clear vision for their use of new innovations,” explains Adam Schwartz.
SSI combines the scientific acumen of experienced medical executives with the expertise of business consultants to support the strategic needs of the Medical Office
One example of SSI’s work is their collaboration with a client that was struggling to align their PV and Information Technology ( IT) departments. This restricted the client from devising a strategy that could meet near-term product development objectives. With SSI’s assistance, the client was able to align the PV and IT teams along with gaining an understanding of their vision and strategies for the two departments from an overall business perspective. In addition, SSI helped the firm develop a 3-5 year roadmap with inputs and insights from both, PV and IT to effectively define future goals.
Going forward, SSI plans to further expand their existing global footprint in New York, New Jersey, Boston, San Francisco, and London to support their clients. “It is crucial for Life Science organizations to have a clear idea and understanding of what they plan to accomplish with a new technology or innovation, and we provide an efficient way to realize business requirements, strategies, and future roadmaps, with our consulting services,” concludes Schwartz.
Company
SSI Strategy
Management
Adam Schwartz, President
Description
SSI provides consulting services to support the needs of the Medical Office including, Medical Affairs, Pharmacovigilance, and Clinical Development by combining business acumen and consulting discipline to service life science industry clients
Koneksa's digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. This collaboration will offer existing clients of both organizations a streamlined relationship offering the industry’s best scientific, technical, and delivery expertise across all phases of the clinical trial and product lifecycle. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development. SSI clients gain access to Koneksa's industry-leading expertise in developing and employing evidence-based digital biomarkers.
“This synergistic partnership is a combination of resources, talent and expertise across two leading science-based organizations with a mission of optimizing and accelerating therapies for patients in need, through greater adoption of digital biomarkers in clinical studies,” said Vik Shah, President and COO of Koneksa. “This expanded partnership is in response to the growing interest from life sciences companies to have an in-house digital biomarker solution, and SSI will enable us to rapidly scale our medical and scientific functions to meet this demand. SSI will also be able to provide clients with leading expertise in digital biomarkers from the Koneksa team, to accelerate clinical trials and bring new life-saving therapies to patients faster.”
“Koneksa’s digital biomarker solutions capture actionable measures that will enable therapeutic developers to efficiently address pre- and post-market evidence requirements at much earlier stages of development,” said Doug Locke, CEO of SSI Strategy. “We particularly see the collaboration as mutually beneficial to many of our rare-disease client partners, in alignment with our growing digital health practice.”
“We look for similar customer-oriented ethos and patient-centric mindsets in our partnerships,” said Kim Kushner, Chief Business Officer, SSI Strategy. “Our engagement over the past year in scaling and expanding Koneksa’s medical function, under the leadership of Koneksa Chief Medical Officer Dr. John Wagner, has confirmed that our interests are highly aligned, and we look forward to this next phase of growth.”